Fig. 4
In vivo ALK+ ALCL lymphomagenesis derived from NA cells. A. Schematic illustration of the experiment: NA1, NA2 and NA3 cells were intravenously injected into NSG mice at 1 month post-transfection. Tumor cells from NA1 cells were injected in secondary recipients (NA1 IIr). In parallel, NA4-E (unsorted cells) and NA5-ECD8 (CD8+) cells were intravenously injected in NSG mice at 15 days post-transfection. IV: intravenous injection. B. Kaplan-Meier survival curve of first and second recipient mice intravenously injected with different pools of NA cells obtained from various time points after transfection (15 days (NA4-E, NA5-ECD8), 1 month (NA1 and NA2) or ALKIma1 cell line). IIr: secondary mouse recipients. C. Flow cytometry assessment of CD45, CD30 and PDL1 expression in tumors derived from NA1 cells (spleen and lymph node) for mouse #148. D. Histologic analysis of tumors derived from NA1 cells: anti-ALK in lung and spleen tumors for mouse #148. E. Histologic analysis of tumors from NA1 cells in skin nodules: H&E staining, anti-CD30, anti-ALK for mouse #150. F. Flow cytometry assessment of CD45, CD30, PDL1, CD4, CD8 and CD3 expression in tumor cells (spleen and lymph node) from mice #925 (injected with NA4-E) and mouse #791 (injected with NA5-ECD8 cells). G. Histologic analysis of tumors in spleen, liver, lung and lymph node from mouse #791 injected with NA5-ECD8 cells: anti-CD4 and anti-CD8